Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

Stopped early · Not applicable

Conditions studied: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease

In brief

The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory bowel disease (IBD) is an important cause of loss of response to therapy that may lead to escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI) or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of response. An alternative approach is the addition of immunomodulator (IM) therapy to counteract the antibody response and regain efficacy of the biologic medication. The investigators' goal is to treat patients' who have lost response to adalimumab or infliximab with an immunomodulator with the goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.

Key facts

Study ID

NCT02413047

Run by

Indiana University

People needed

3

Starts

2015-05-01

Expected to finish

2018-02-01

Last updated by the study team

2019-11-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with inflammatory bowel disease who on are stable doses of infliximab or adalimumab for at least 3 months who experience a secondary loss of response to the medication based on clinical symptoms.
• Presence of at least one objective marker of active disease: active disease based on endoscopy, elevated fecal calprotectin or serologic markers of inflammation (C-reactive protein or sedimentation rate).
• Crohn's patients have a Harvey Bradshaw index >5
• Ulcerative colitis patients have a Ulcerative Colitis Clinical Score > 5
• Have an undetectable or inadequate trough level of infliximab or adalimumab and detectable ATI or ADA.
• Oral corticosteroid therapy is allowed. (prednisone at a stable dose ≤30 mg/day, budesonide at a stable dose ≤9 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have recently been initiated

You may not qualify if…

• Previous noncompliant with medications
• < 18 years of age or >80 years of age.
• Congestive heart failure
• Abnormal liver tests alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 2 × the upper limit of normal (ULN) or leucopenia WBC count <3 × 109/L
• Pregnant or planning on becoming pregnant.
• Active tuberculosis or hepatitis B infection
• Any cancer within the past 5 years. (Exception non-melanomatous skin cancer.)
• Receiving any immunomodulator therapy within the past 3 months
• Evidence of or treatment for C. difficile infection within 60 days or other intestinal pathogen within 30 days prior to enrollment
• Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis) within 30 days of the initial screening visit
• Any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine
• Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)
• Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety
• Unable to give own informed consent

Where it is running

• Indiana University Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.